ITO EN Oi Ocha Green Teas Coming Soon to Walmart
30.7.2019 15:15:00 EEST | Business Wire | Press release
ITO EN (North America) INC. the global leaders of green tea and innovators of healthy beverages today announced that their Oi Ocha ready-to-drink green tea brand, will soon be available in Walmart stores nationwide. Slated for placement in October 2019 with two unsweetened flavors- ITO EN’s premium Oi Ocha green tea, Japan’s top selling brand and Jasmine Green Tea, a popular green tea infused with jasmine flowers. The award-winning teas are celebrated for their naturally smooth taste and clean finish, brewed with ITO EN’s proprietary brewing method using whole tea leaves without artificial additives, flavors or colors, and powders or concentrates. The authentic and refreshing teas are Non-GMO certified with natural catechin tea antioxidants, natural Vitamin C (Ascorbic Acid) and zero calories. Each packaged in a convenient on the go 16.9 fl. oz recyclable PET bottle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190730005425/en/
ITO EN Oi Ocha and Jasmine Green Tea. (Photo: Business Wire)
“With a growing number of consumers looking for authentic and healthy beverages, we could not be more excited to expand Ito En’s tea products into Walmart stores nationwide,” says Jim Hoagland, COO at ITO EN (North America) INC. “With Walmart responding to the growing consumer interest for high-quality, authentic and better-for-you products, we are confident that our traditional unsweetened green teas are a great fit for Walmart and their customers.”
The Oi Ocha brand has been growing exponentially in the U.S. market as consumer demand for authentic and healthier beverages continues to grow across the specialty, mainstream markets, and food service channels. The partnership with Walmart not only broadens ITO EN’s brand awareness and distribution but will also give accessibility to a better-for-you beverage to the everyday consumer. With green tea gaining popularity for its health benefits while consumers seek sugar free beverages, unsweetened Oi Ocha teas are ideal to integrate into daily life.
ITO EN is specifically known for its commitment to tea expertise and sustainable practices that are reflected across all of its award-winning brands. With over 50 years of tea expertise, the company is dedicated to authenticity, preserving its culture while creating global innovation for the tea and beverage industry. ITO EN is proud to have ranked #18 in FORTUNE's top 50 Companies that have made an important social or environmental impact through its profit-making strategy and operations. The company was also awarded a sustainability award for its used tea leaf recycling program, creating innovative products from a eco-friendly synthetic resin made from used tea leaves. For more information on ITO EN and its products, please visit www.itoen.com.
About ITO EN:
ITO EN (North America) INC., a subsidiary of ITO EN (Japan) LTD., is an innovative beverage industry leader dedicated to creating authentic products that embody the company’s five principles of Natural, Healthy, Safe, Well-designed and Delicious. With over 50 years of tea expertise in Japan, ITO EN is dedicated to authenticity, preserving its culture while creating global innovation, making it known as Japan’s #1 green tea purveyor with award-winning brands, including TEAS’ TEA Organic®, Oi Ocha®, ITO EN Shots® and matcha LOVE®. ITO EN’s strong commitment to social and environmental impact manifests in its partnerships with regional farmers and governments to stimulate local economies, development of sustainable procurement practices and nurture a new generation of tea farming. To learn more about ITO EN, visit www.itoen.com. ‘Like’ us on Facebook or follow us on Twitter and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190730005425/en/
Contact information
Rona Tison
ITO EN (North America) INC.
rtison@itoen.com
T. 707-327-6413
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom